Short answer
GYRE THERAPEUTICS, INC. (GYRE) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $33M (up 7.8% year over year) with net income of −$3M.
Q3 2026 key financials · XBRL
- Revenue
- $33M
- +7.8% YoY · +6.2% QoQ
- Net income
- −$3M
- −142.4% YoY · +89.1% QoQ
- Operating margin
- -4.6%
- EPS (diluted)
- −$0.03
- −200.0% YoY · +81.3% QoQ
Source: XBRL data from the GYRE THERAPEUTICS, INC. (GYRE) Q3 2026 10-Q on SEC EDGAR. USD.
GYRE THERAPEUTICS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $32.9M, up $0.2M or 1% YoY, driven by ETUARY sales despite lower Contiva and Etorel revenue
- Operating loss $1.5M vs operating income $1.5M YoY, operating margin (4.6%) vs 4.6%
- ETUARY best performer, higher sales volumes; Contiva and Etorel worst, lower revenue after centralized procurement
- Cash and equivalents $41.6M vs $49.2M, operating cash outflow $17.5M for nine months
- F351 NDA decision expected by end-2026 or Q1 2027, with Cullgen integration and clinical spending as headwinds
Risk Factors
- No material changes from the Annual Report and Q2 Quarterly Report risk factors
- Undisclosed risks: unknown or currently immaterial factors could materially adversely affect results
- Clinical-stage business risk: carried-forward Annual Report and Q2 Quarterly Report risks remain applicable
- Regulatory risk: carried-forward SEC-disclosed risks could materially affect financial position
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GYRE THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.